The clinical application of the CD3ζ-based CAR T cells in patients suffering from ovarian cancer [68], neuroblastoma [69], and non-Hodgkin’s lymphoma (NHL) [18] revealed limitations. The gene discussed is CD247; the disease is non-Hodgkin lymphoma.